Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02203760 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pazopanib Vs. Pazopanib Plus Gemcitabine

Study acronym: PazoDoble
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 15, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 3 of 9 sitesv6
  2. Primary completion date: Dec 2022 to Dec 31, 2024v5 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 107 to confirmed 58
    • Study completion date: Dec 2023 to Dec 31, 2024
    • Site details revised at 9 of 9 sites
  3. Start date: Sep 2013 to Oct 16, 2019
    • Study sites: 7 to 9
    • Secondary endpoints revised (6)
    v4
  4. Re-verified, no change to tracked fieldsv3
  5. Lead sponsor: University Medicine Greifswald to North Eastern German Society of Gynaecological Oncologyv2 Show 9 more changesShow less
    • Primary completion date: Mar 2015 to Dec 2022
    • Study sites: 13 to 7
    • Study completion date: Jun 2016 to Dec 2023
    • Secondary endpoints: details revised at 5 of 6 entries
    • Primary endpoint revised
    • Study description expanded, about 207 words
    • Collaborators revised (2)
    • Study title shortened, about 25 words
    • Eligibility criteria expanded, about 4 words
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a prospective, randomized, open-label, multicenter phase II trial in order to determine progression-free survival of patients with refractory or relapsed metastatic uterine leiomyosarcomas or other metastatic uterine tumours.
Trial Details
NCT Number NCT02203760
Lead Sponsor North Eastern German Society of Gynaecological Oncology
Collaborators: Novartis Pharmaceuticals, medac GmbH
Conditions
(from sponsor)		 Leiomyosarcoma or Carcinosarcoma
Related terms Carcinosarcoma, Leiomyosarcoma, Recurrence
Enrollment 58 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov